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impact of this on the treatment of asthma. METHODS: Our
submission to NICE reviewing the relative value of alternative
products, utilised a cost-minimisation approach, recognising that
there was little evidence of clinical differentiation between the
ICS. RESULTS: It was estimated that a total switch to QVAR
upon withdrawal of CFC based BDP, would result in only a
modest 6% increase in costs to the NHS, but could result in
overall cost savings if it were substituted for more costly ICS
alternatives, such as ﬂuticasone propionate or budesonide. CON-
CLUSION: There remain concerns that NICE may overlook the
current political and socioeconomic imperatives and provide
Guidance that does not consider appropriate BDP dosing or
recognise that the environment will change over its period of
jurisdiction.
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OBJECTIVES: Frequent use of short-acting beta agonists (SABA)
inhalers, along with insufﬁcient use of concurrent steroid inhal-
ers, is often the cause of suboptimal management of the disease.
The aim of the study is to identify the heavy purchasers of SABA
and improve the management of there disease. METHODS: All
Maccabi Healthcare Services (MHS) patients in two areas in the
Shfela district who consumed al least 4 SABA inhalers during
2005 were identiﬁed using MHS’s computerized database. The
patients’ primary care physicians (PCP) were briefed with the
ﬁndings and where presented the current evidence based medi-
cine (EBM) clinical guidelines for proper asthma treatment in a
group meetings with pulmonologist. Later the PCP attend to two
days workshop dealing with appropriate asthma treatment,
patient’s adherence and practicing clinical scenarios with profes-
sional actors. A 3rd meeting included case presentations and
further discussions with a pulomonologist. A control group con-
sisted of patients of PCPs in other areas in the Shfela district
which didn’t participate in the study. RESULTS: One hundred six
patients were in the intervention group. 85 required more then 2
SABA inhalers in the ﬁrst 6 month after intervention (decrease of
20%). In the control group there was a 4% increase in patients
using more than 2 SABA inhalers during the same period (185 to
193). CONCLUSION: We have observed a signiﬁcant improve-
ment in SABA consumption. This improvement applies that edu-
cational efforts on applying EBM clinical guidelines for proper
asthma treatment and providing simple tools for dealing with
patients’ adherence, can improve management and control of
asthma and can lower asthma’s treatment expenses. We suggest
similar interventions on other chronic diseases.
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OBJECTIVES: Clinical efﬁcacy and cost-effectiveness of immu-
notherapy in allergic disease caused by various allergens is dem-
onstrated by several published studies, but economic value is still
far from being appreciated by local decision makers. Scope of
this work was to provide the Regional decision makers with real
world information on the use and impact of immunotherapy in
terms of efﬁcacy on symptoms, use and cost of drugs in patients
affected by rhinoconjunctivitis (RC) with or without asthma (A),
caused by ragweed seasonal allergy. METHODS: Observational
study, of precoseasonal sublingual (SLIT) or preseasonal subcu-
taneous immunotherapy (SCIT) versus non-immunotherapy
(NSIT). Patients enrolled by a network of specialist centres from
Lombardia, were randomly assigned to one of the study groups
and were allowed to take any additional medication needed to
control RC and A symptoms; effectiveness was measured as
global symptom score rated by the patient on a VAS at last visit;
drug consumption was measured as days of medication recorded
by the patient on a weekly diary card during the peak season;
drug cost was calculated by applying Italian NHS prices.
RESULTS: For the ﬁrst year of immunotherapy, 163 adults were
analyzed (SLIT N = 67 M = 48%, age 39+/-9.1; SLIT N = 34
M = 62%, age 41+/-8.1; NSIT N = 62 M = 53%, age 36+/-9.2);
25% of SLIT patients were affected by A as compared to 47% of
SCIT and 37% of NSIT patients; 55% of SLIT patients were
treated with high dose SLIT. The mean number of drug treatment
days/patient was lower for SLIT patients 26.15+/-30.1 vs. NSIT
58.7+/-43.4 (p < 0.0001) and for SCIT patients 33.0+/-45.7 vs
NSIT 58.7+/-43.4 (p < 0.05); similarly the mean total cost/
patient of drug treatment was lower with SLIT €28.19 vs SCIT
€33.9 and NSIT €59.2. CONCLUSION: SLIT and SCIT can
effectively reduce use and cost of drug treatment in adults
affected by rhinoconjunctivitis with/without asthma caused by
ragweed in Lombardia.
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OBJECTIVES: Formoterol/budesonide (BUD/FORM) and sal-
meterol/ﬂuticasone propionate (SAL/FLU) have been shown to
be effective in the treatment of asthma. This retrospective, obser-
vational study compared characteristics of patients initiating
treatment with BUD/FORM or SAL/FLU in routine clinical prac-
tice, subsequent treatment outcomes and resource utilisation.
METHODS: A cohort of German patients diagnosed with
asthma, followed from 12 months before to 12 months after
treatment initiation with BUD/FORM or SAL/FLU, was ex-
tracted from a longitudinal, primary care database of records
collected from June 2000 to June 2006. The primary outcome
was the proportion of successfully treated patients deﬁned
according to utilisation of short-acting beta-agonists (SABA) and
switches or addition of controller medications during the post-
index year. Secondary outcomes included resource utilisation and
acute exacerbations, deﬁned as at least one oral corticosteroid
(OCS) prescription and/or hospitalisation related to asthma.
Regression models were used to adjust for patient characteristics,
including treatment history. RESULTS: The BUD/FORM and
SAL/FLU groups included 1,456 and 982 patients, respectively.
Prior to treatment initiation, patients in the BUD/FORM group
received less asthma-related OCS prescriptions (mean difference:
-0.049, p = 0.0328) but utilisation of SABA, ICS and LABA was
similar. In the year following treatment initiation, patients initi-
ating on BUD/FORM had a greater probability of treatment
success (OR = 1.54, p = 0.0001), fewer acute exacerbations
A402 Abstracts
(-40.2%, p = 0.0007) and fewer physician visits (-4.4%,
p = 0.0259), than those on SAL/FLU, after controlling for base-
line characteristics. The BUD/FORM patients were less likely to
switch to an alternative ICS + LABA combination (OR = 0.58,
p = 0.0067). Numbers of hospitalisations, referrals and work
absences did not differ between groups. CONCLUSION: BUD/
FORM was associated with a lower probability of treatment
switches, fewer acute exacerbations, and with similar or lower
resource utilisation compared with SAL/FLU. Although the
groups appeared well matched at treatment initiation, these
results should be interpreted with caution given the observational
nature of this study.
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OBJECTIVES: EPR-2 guidelines were developed to improve
medication prescribing for patients with persistent asthma and to
control acute exacerbations of asthma. In addition these guide-
lines also encourage physician provided asthma education. Little
is known about prescribing adherence to EPR-2 guidelines. This
study examined physician adherence to EPR-2 asthma medica-
tion prescribing guidelines and determine patient and physician
factors associated with prescribing of asthma medications.
METHODS: This study was a cross-sectional retrospective
analysis of complex NAMCS physician visit survey data from
1998 through 2004. Data were extracted on all patient s with an
ICD-9 code for asthma (493.XX) and reason for visit as
‘asthma’. Unit of analysis was individual patient visit. Dependent
variables in analyses were speciﬁc type of drug class. Independent
variables were various patient and physician factors. Logis-
tic regression analysis was used to assess study objectives.
RESULTS: Asthma patients in 2002 were 3.3 times more likely to
be prescribed controller medications compared in 1998. Findings
in 2004 were not signiﬁcant. Elderly patients were 54% as likely
to receive controller medication compared to the 35–64 year age
group. Patients other than whites or African Americans are 40%
as likely to receive controller asthma medication compared
to whites. Physicians were 6.3 times more likely to prescribe
long acting beta agonists compared to 1998. Physicians without
ownership stake in their practice were 1.9 times more likely to
provide asthma education to their patients compared to those
who owned their practice. CONCLUSION: This study using US
outpatient setting data provides evidence that physician prescrib-
ing of asthma pharmacotherapy in the US does not adequately
comply with EPR-2 treatment guidelines.
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OBJECTIVES: Medical care costs for rhinitis are primarily
driven by patient care-seeking behavior and physician prescrib-
ing patterns, which may evolve over time. Estimating a model of
real-world rhinitis treatment from clinical trial data is not fea-
sible due to short trial durations and protocol-driven care. There-
fore, we used U.S. health care claims data to model rhinitis
treatment patterns and estimate the budgetary impact of a novel
rhinitis therapy. METHODS: We developed a three-year budget-
ary impact model of rhinitis using Markov-modeling techniques.
Transitions between treatment regimens (monotherapy, dual-
combination therapy, tri-combination therapy), treatment pat-
terns, (therapy switching, add-on rates), and associated medical-
care costs, were estimated from a large claims database, by
identifying rhinitis patients and tracking changes in therapy over
time. Budgetary impact of a novel treatment was assessed for
three effectiveness scenarios, where the switching/add-on rates
relative to ﬂuticasone propionate, an existing rhinitis therapy,
were 50% lower (Scenario 1), 25% lower (Scenario 2) and
identical (Scenario 3). The novel treatment was assumed to be
priced the same as ﬂuticasone propionate and have a market
share of 10%. RESULTS: The claims analysis found annual rates
of treatment switching, add-on, and remaining on initial therapy
ranging from 6–18%, 20–28%, and 62–72%, respectively,
for currently existing rhinitis therapies. Annual rhinitis-related
medical costs associated with each treatment pattern were $666,
$657, and $558, respectively. In Scenario 1, the model predicted
the per-patient-per-month (PPPM) budgetary impact for the
novel treatment to be -$0.06, -$0.09, and -$0.11, in years 1–3,
respectively. Scenarios 2 and 3 had corresponding PPPM results
of $0.00, -$0.01, and -$0.01, and $0.05, $0.06, $0.08. CON-
CLUSION: Using claims data and Markov-modeling techniques,
we found that budgetary impact can be materially affected by
rates of treatment switching/add-on. Detailed, claims-based data
are required for this type of analysis, given the real-world nature
of treatment patterns and associated medical costs.
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OBJECTIVES: We hypothesized that the average medication
possession ratio (MPR) for controller medications in adult asth-
matic populations may be misleading as a basis for evaluating
adherence. METHODS: MPR distributions were determined
from analysis of the Pharmetrics database for the period April
2004 to March 2005. We assessed MPRs for those plan members
exclusively on one of the three major controller medication
groups: inhaled corticosteroids, combined inhaled corticoster-
oids and long acting beta agonists, and leukotriene modiﬁers.
MPR were deﬁned in terms of annual days supplied (range 0 to
1.0). RESULTS: Overall, for the study population (n = 17,581)
5,806 were exclusively on combination therapy (33.8%), 2,689
were exclusively on leukotriene modiﬁers (15.3%) and 2,106
exclusively on inhaled corticosteroids (12.0%). Average (median)
MPRs were 0.51 (0.57) for combination therapy; 0.55 (0.63) for
leukotriene modiﬁers; and 0.39 (0.33) for inhaled corticoster-
oids. Distributions of MPRs for these groups showed signiﬁcant
bi-modality (a “U” shaped MPR proﬁle). This characteristic was
most pronounced for the combined controller group medications
and the leukotriene modiﬁers where the frequency distributions
were almost identical. For the combined medications 32.2% of
adults reported a MPR < 0.2, with 19.0% and 28.9% reporting
MPRs of 0.6 to 0.79 and 0.8 to 1.0 respectively. The correspond-
ing estimates for leukotriene modiﬁers were 27.5%, 19.6%
and 33.1% respectively. For inhaled corticosteroids, 45.2% of
patients reported an MPR < 0.2 with only 33.2% reporting an
MPR > 0.6 (15.5% > 0.8). CONCLUSION: This analysis con-
ﬁrms the hypothesis that average MPR may be a misleading
indicator of adherence in patients taking combined controller
medications and leukotriene modiﬁers. We suggest an approach
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